Monte Rosa MRT-8102 Phase 1 data show ASCVD biomarker normalisation
Monte Rosa Therapeutics has reported Phase 1 results from GFORCE-1, a 108-subject study of MRT-8102 in obese patients with elevated cardiovascular disease risk, saying the NEK7-directed molecular glue degrader (MGD) reduced a broad panel of atherosclerotic cardiovascular disease (ASCVD) biomarkers to levels comparable with those seen in healthy volunteers.
The NASDAQ-listed company said NEK7 degradation was robust and sustained across all three once-daily dose levels tested, 5 mg, 20 mg, and 40 mg, with a median protein reduction of approximately 80 to 90% at each level. Critically, the biomarker responses were broadly similar across doses, a profile that gives the company flexibility in selecting dose for Phase 2 without an obvious efficacy cliff.
What the data showed
Among the key pharmacodynamic findings, median values of calprotectin, S100A12, and SAA, damage-associated molecular patterns linked to plaque progression and instability, fell by 56%, 46%, and 51% respectively. IL-6 and high-sensitivity CRP, standard markers of systemic inflammation, dropped by medians of 54% and 85%. The thrombogenic protein fibrinogen was reduced by a median of 28%. Monte Rosa also reported a 24% median reduction in lipoprotein(a), an independently validated cardiovascular risk factor for which treatment options remain scarce.
An intriguing signal emerged in the roughly 30% of participants who carried NLRP3 risk alleles: these individuals showed significantly elevated baseline levels of damage-associated molecular patterns and IL-1β, and appeared to respond more strongly, suggesting a genetically enrichable subpopulation that could sharpen Phase 3 design.
Chief medical officer Filip Janku described the dataset as "the most comprehensive translational data set reported to date for the NEK7/NLRP3 pathway." The company said no serious adverse events were recorded and that treatment-emergent adverse event rates were similar to placebo, 33% versus 30%, with no increased infection signal over the four-week dosing period and four weeks of follow-up.
Phase 2 plans and competitive context
Monte Rosa is advancing MRT-8102 into three Phase 2 programmes. GFORCE-2, a Phase 2b study in stable coronary artery disease with residual inflammation, is expected to begin in the first half of 2027, pending completion of long-term preclinical toxicology work. GEMINI-1, targeting gout flare prevention, is planned for the fourth quarter of 2026 or the first quarter of 2027, with initial data anticipated in the second half of 2027. GALAXY-1, covering moderate to severe hidradenitis suppurativa, is also slated for the first half of 2027.
The NLRP3 inflammasome has attracted sustained industry attention as a cardiovascular target following the CANTOS trial, which demonstrated that IL-1β blockade with canakinumab reduced cardiovascular events in patients with elevated hsCRP. That proof of concept drew significant interest in the pathway, but IL-6 receptor blockers such as ziltivekumab and direct NLRP3 inhibitors from companies including Novo Nordisk and Agenus are now competing for the same biological territory. Monte Rosa's argument for attacking NEK7 at the upstream activator of the inflammasome, rather than individual downstream cytokines, is that simultaneous suppression of multiple DAMPs and interleukins could offer a broader therapeutic effect. The GFORCE-1 data are consistent with that hypothesis, though cardiovascular outcome evidence remains years away.
The lipoprotein(a) reduction is a notable secondary finding. Monte Rosa notes the reduction is comparable in magnitude to that seen with PCSK9 inhibitors, an observation that, if replicated in longer studies, would add commercial appeal, as approved Lp(a)-targeted therapies from Silence Therapeutics and Novartis are still navigating late-stage development. The company's molecular glue platform, built on its QuEEN discovery engine that integrates structural biology, AI-guided chemistry, and proteomics, underpins a broader pipeline that also spans oncology and autoimmune disease.